Navigation Links
Laureate Pharma Appoints Gary Swan as Vice President of Operations
Date:2/14/2008

lopment and manufacturing of virus-inactivated blood products and the purification of proteins from blood components. At VI, Gary was responsible for strategic planning and daily operation of a 100,000 SF sterile product biopharmaceutical facility with a staff of 200. Gary has a BS in Biology from Auburn University, Auburn, AL.

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE; http://www.safeguard.com), which provides growth capital for entrepreneurial and innovative technology and life sciences companies through expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400 or info@laureatepharma.com, or visit http://www.laureatepharma.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
2. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
3. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
4. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
5. Pharmaxis to Apply to Market Bronchitol in Australia
6. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
7. Vion Pharmaceuticals Holds Special Meeting of Stockholders
8. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
9. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
10. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
11. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... at the University of California, San Diego for a ... load bearing Gravitic™ MRI (Magnetic Resonance Imaging) with that ... renowned for its continued pursuit of improved healthcare by ... Spinal MRI is an extremely valuable tool for evaluating ...
(Date:5/21/2013)... Lake, MN (PRWEB) May 21, 2013 The ... trade show display solution for sales and marketing teams looking ... Displays describes the kit as “everything you’ll need to ... Fusion Fabric Display Kit comes with a number of displays ... all-around trade booth 20 feet by 20 feet in size. ...
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2New Laboratory Temperature Controller by Oven Industries 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...
... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...
... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...
Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3Scientists develop new technique that could improve heart attack prediction 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: